Familial Hypertriglyceridemia Clinical Trials

Find Familial Hypertriglyceridemia Clinical Trials Near You

A Multi-center, Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of HRS-7249 in Patients With Hypertriglyceridemia

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This is a Phase II multi-center, open-label extension (OLE) clinical trial of HRS-7249, a GalNAc-conjugated APOC3-targeted siRNA injection, enrolling two cohorts of participants. Cohort 1 includes subjects who completed parent study HRS-7249-201 within 24 weeks; Cohort 2 newly recruited patients with fasting triglyceride (TG) ≥2.3 mmol/L aged 18-79 years. All participants receive subcutaneous HRS-7249 for a 48-week treatment period followed by a 24-week safety follow-up phase, with two dosing regimens. The primary objective is to assess long-term safety and tolerability of repeated HRS-7249 administration. Secondary objectives include evaluating sustained lipid-lowering effects on TG, APOC3 and other lipid profiles, impacts on glycometabolism, incidence of acute pancreatitis and major adverse cardiovascular events (MACE), long-term pharmacokinetic/pharmacodynamic (PK/PD) profiles, and anti-drug antibody (ADA) dynamics. All safety assessments including vital signs, physical examinations, laboratory tests, 12-lead ECG, injection site reactions and adverse events will be collected throughout the study. Lipid parameters, HbA1c, pancreatitis and cardiovascular events will be monitored to characterize the clinical benefit-risk profile of long-term HRS-7249 therapy in hypertriglyceridemia patients. A total of at least 400 subjects will be enrolled nationwide in China.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 79
Healthy Volunteers: f
View:

⁃ \- Cohort 1 (Roll-over participants from HRS-7249-201)

• Able to understand trial procedures, voluntarily participate and provide written informed consent;

• Completed last visit of parent study HRS-7249-201 within 24 weeks prior to screening;

• Male or female subjects aged ≥18 and \<80 years at consent signature. Cohort 2 (Newly enrolled participants)

⁃ 1\. Able to understand trial procedures, voluntarily participate and provide written informed consent; 2. Fasting triglyceride ≥2.3 mmol/L at screening; 3. Male or female subjects aged ≥18 and \<80 years at consent signature.

Locations
Other Locations
China
The First Affiliated Hospital of Shandong First Medical University (Qianfo Shan Hospital of shandong province).
RECRUITING
Jinan
Shanghai Chest Hospital
RECRUITING
Shanghai
Contact Information
Primary
Chanjuan Deng, MM
Chanjuan.deng@hengrui.com
0518-82342973
Backup
Jianpeng Su, MS
jianpeng.su.js18@hengrui.com
0518-82342973
Time Frame
Start Date: 2026-09-11
Estimated Completion Date: 2028-10-15
Participants
Target number of participants: 400
Treatments
Experimental: Arm 1
HRS-7249 Injection; Low dose, subcutaneous administration
Experimental: Arm 2
HRS-7249 Injection; High dose, subcutaneous administration
Sponsors
Leads: Fujian Shengdi Pharmaceutical Co., Ltd.

This content was sourced from clinicaltrials.gov